Who Makes This Medication?
Tradjenta is marketed by Boehringer Ingelheim Pharmaceuticals, Inc., and Eli Lilly and Company.
How Does Tradjenta Work?
Tradjenta is part of a class of diabetes medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. DPP-4 is an enzyme that breaks down incretin hormones. As a DPP-4 inhibitor, Tradjenta slows down the breakdown of incretin hormones, increasing the level of these hormones in the body. It is this increase in incretin hormones that is responsible for the beneficial actions of Tradjenta, such as increasing insulin
production in response to meals and decreasing the amount of glucose (sugar) that the liver produces.
Because incretin hormones are more active in response to higher blood sugar levels, the risk of dangerously low blood sugar levels (hypoglycemia) is low with Tradjenta.